Halozyme director receives stock, option grants

HALOZYME THERAPEUTICS, INC. director Barbara Gayle Duncan received equity compensation in the form of restricted stock units and stock options.

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. director Barbara Gayle Duncan received equity compensation in the form of restricted stock units and stock options. She was granted 3,796 shares of common stock as annual RSUs and an option for 6,040 shares of common stock.

The RSUs and options are part of the issuer's director compensation program and each RSU represents one share of common stock. Both awards vest in full on the earlier of May 5, 2027 or the date of the next annual meeting of stockholders. Following the RSU grant, she holds 23,715 common shares directly, and the new option has an exercise price of $65.87 per share and expires on May 5, 2036.

Insider Trade Summary

Grant/Award: 9,836 shares

Grant/Award 2 txns

Insider DUNCAN BARBARA GAYLE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	6,040	$0.00	$0.00
Grant/Award	Common Stock	3,796	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 6,040 contracts (Direct); Common Stock — 23,715 shares (Direct)

Footnotes (2)

1. F1. Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
2. F2. Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Key Figures

RSU grant: 3,796 shares Option grant size: 6,040 shares Option exercise price: $65.87 per share +3 more

6 metrics

RSU grant 3,796 shares Annual restricted stock unit grant to director on May 5, 2026

Option grant size 6,040 shares Annual stock option grant to purchase common stock

Option exercise price $65.87 per share Exercise price for 6,040-share stock option

Option expiration May 5, 2036 Expiration date of director stock option grant

Shares held after RSU grant 23,715 shares Direct common stock holdings following RSU award

Vesting date Earlier of May 5, 2027 or next annual meeting Vesting schedule for RSUs and stock option

Key Terms

restricted stock unit ("RSU"), Directors Deferred Equity Compensation Plan, annual stock option grant

3 terms

restricted stock unit ("RSU") financial

"Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program."

Directors Deferred Equity Compensation Plan financial

"These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan"

annual stock option grant financial

"Represents annual stock option grant under the Issuer's director compensation program."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did HALO director Barbara Duncan receive on this Form 4?

Barbara Duncan received 3,796 restricted stock units and an option to purchase 6,040 shares of Halozyme common stock. These grants are part of the company’s director compensation program and were reported as acquisitions, not open-market purchases or sales.

When do Barbara Duncan’s new HALO restricted stock units and options vest?

Both the 3,796 RSUs and the 6,040-share stock option vest in full on the earlier of May 5, 2027 or the date of Halozyme’s next annual meeting of stockholders. This creates a single vesting event tied to her ongoing board service.

What is the exercise price and expiration date of Barbara Duncan’s new HALO stock option?

The new Halozyme director stock option covers 6,040 shares at an exercise price of $65.87 per share. The option expires on May 5, 2036, giving a long-term window for potential exercise if vesting and other conditions are met.

How many HALO shares does Barbara Duncan own after this Form 4 transaction?

After the grant of 3,796 RSUs, Barbara Duncan’s reported direct holdings of Halozyme common stock are 23,715 shares. This figure reflects her position following the award and highlights that the Form 4 shows an increase, not a reduction, in equity exposure.

Are Barbara Duncan’s HALO restricted stock units immediately settled in shares?

The filing notes the RSUs are subject to a directors deferred equity compensation plan. Shares of Halozyme common stock are released to Barbara Duncan upon completion of her service as a director, so settlement is deferred rather than immediate upon grant or vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 07:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DUNCAN BARBARA GAYLE

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		A		3,796(1)	A	$0	23,715	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$65.87	05/05/2026		A		6,040		(2)	05/05/2036	Common Stock	6,040	$0	6,040	D

Explanation of Responses:

1. Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

2. Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)